he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
检视信源地址
- 2022-05-04颅脑创伤看似是急病,似乎也是慢病
- 2022-04-262013年的国际抗癫痫联合会抗癫痫药使用指南
- 上海率先探索异地就医门诊费直接结算
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫治疗障碍仍难以克服
- 月经性癫痫患者妊娠期癫痫控制更好
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫猝死:凶手是谁?
- 2016AAN:神经专家发表了有前途的专业见解
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 癫痫患者手术评估新型工具
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 脑梗死的症状是什么有这些前兆要谨慎
- 为什么要定期复查脑电图?
- 2015第31届国际癫痫大会(IEC)
- 癫痫治愈费用
- 预测癫痫患者再入院风险
- UCB的Vimpat癫痫新适应症在美国获批
- 中医如何治疗癫痫 癫痫预防?
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 抗癫痫药物预防新发癫痫:任重而道远
- 综述:癫痫持续状态诊治最新进展
- FDA警告怀孕期间使用丙戊酸钠药物
- 2013国际抗癫痫联合会抗癫痫药用指南
- 三庚酸酯可治疗1型转运体缺陷综合征
- 儿童癫痫病的治疗款项
- 洋甘菊精油的洗澡法 洋甘菊精油能预防感冒
- 睡觉时马上抽搐一下 新生儿睡觉抽搐怎么办
- FDA批准Aptiom用于治疗患者的病症发作
- 癫痫病吃掉什么可以控制
- 帕金森氏症的症状是什么
- 癫痫病的疾病主要是什么
- 类亨廷顿病综合征鉴别诊断的7种医学特点
- 北京癫痫病切除费用
- 脑梗的症状有哪些 有了这些诱发要谨慎
- 小儿帕金森氏症的早期症状 帕金森氏症的原因
- 癫痫持续状态应该如何妥善处理?
- 癫痫病的前期有什么疼痛
- 癫痫的末期的症状有哪些
- 青少年得癫痫病的疾病是什么